Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Innovative peptide stapling system targets hard-to-treat cancers

3

Mar 2026

Innovative peptide stapling system targets hard-to-treat cancers

Researchers at the University of Bath have developed a new technology that uses bacteria to build, chemically stabilize, and test millions of potential drug molecules inside living cells, making it much quicker and easier to discover new treatments for difficult-to-treat cancers.

Minimally invasive ablation effective for early-stage kidney cancers

3

Mar 2026

Minimally invasive ablation effective for early-stage kidney cancers

A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive procedure called ablation is as effective as surgery for treating small kidney cancers, with faster recovery and fewer complications. Results of the study were published today in Radiology, a journal of the Radiological Society of North America (RSNA).

New blood biomarker may detect Alzheimer’s pathology more accurately

3

Mar 2026

New blood biomarker may detect Alzheimer’s pathology more accurately

Researchers compared total plasma pTau217 with a brain-derived pTau217 assay to determine which better identifies Alzheimer’s disease–related amyloid and tau pathology. Brain-derived pTau217 showed strong diagnostic performance and appeared less affected by kidney dysfunction, supporting its potential as a more specific blood biomarker for Alzheimer’s disease.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.